Lanham O'Dell & Company, Inc. Ocugen, Inc. Transaction History
Lanham O'Dell & Company, Inc.
- $182 Million
- Q2 2024
Shares
3 transactions
Others Institutions Holding OCGN
# of Institutions
108Shares Held
66.5MCall Options Held
516KPut Options Held
272K-
Black Rock Inc. New York, NY17.9MShares$20.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$17.7 Million0.0% of portfolio
-
State Street Corp Boston, MA14.8MShares$16.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA5.9MShares$6.73 Million0.0% of portfolio
-
Rafferty Asset Management, LLC New York, NY1.08MShares$1.23 Million0.01% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $247M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...